8-K/ALeadership Changes

BRISTOL MYERS SQUIBB CO 8-K/A Report, Executive Changes (Oct 31, 2023)

Filed October 31, 2023For Securities:BMYCELG-RIBMYMP

Summary

This 8-K/A filing from Bristol Myers Squibb (BMY) provides an update on leadership transitions and associated compensation, primarily concerning the CEO role. Effective November 1, 2023, Dr. Christopher Boerner will assume the CEO position, taking over from Dr. Giovanni Caforio, who will transition to Executive Chairman. This amendment clarifies that Dr. Caforio will not stand for re-election to the Board and will retire on April 1, 2024, at which point Dr. Boerner will also assume the role of Chairman of the Board. The filing details Dr. Boerner's new compensation package as CEO, including a base salary of $1,500,000, a target bonus of 150% of base salary, and additional long-term incentive awards valued at $1,600,000. Dr. Caforio's compensation remains unchanged during his transition to Executive Chairman, but he will not receive further long-term incentive awards. Investors should note the structured handover and the confirmation of Dr. Boerner's leadership into the Chairman role.

Key Highlights

  • 1Dr. Christopher Boerner appointed CEO, effective November 1, 2023.
  • 2Dr. Giovanni Caforio to transition from CEO to Executive Chairman, effective November 1, 2023.
  • 3Dr. Caforio will retire from the Board of Directors on April 1, 2024, and will not stand for re-election.
  • 4Dr. Boerner will assume the role of Chairman of the Board, effective April 1, 2024, with no additional compensation for this role.
  • 5Dr. Boerner's new CEO compensation includes a $1.5M base salary, 150% target bonus, and $1.6M in long-term incentives.
  • 6Dr. Caforio's compensation remains unchanged during his Executive Chairman transition period.
  • 7The Board size will be set at eleven effective April 1, 2024, following Dr. Caforio's retirement.

Frequently Asked Questions

This 8-K amendment provides updated information regarding leadership changes at Bristol Myers Squibb, specifically detailing the transition of the CEO role and executive chairman duties, as well as clarifying the compensation packages for these roles and future board leadership.

As CEO, Dr. Boerner will receive an annual base salary of $1,500,000, be eligible for an annual bonus plan with a target opportunity of 150% of his base salary, and receive additional long-term incentive awards valued at $1,600,000, comprising performance share units and market share units.

Dr. Caforio will serve as Executive Chairman of the Board starting November 1, 2023. His annual salary and bonus opportunity will remain unchanged during a transition period through April 1, 2024. He will not receive any further long-term incentive awards in his role as Executive Chairman.

Dr. Boerner is appointed Chairman of the Board effective April 1, 2024, immediately following Dr. Caforio's retirement from the Board. He will not receive separate compensation for this Chairman role.